Inhalation therapy in invasive and noninvasive mechanical ventilation

Current Opinion in Critical Care

Volumn 13, Issue 1, 2007, Pages 27-38

  Dhand, Rajiv ^a  

^a University of Missouri   (United States)

Author keywords

Aerosols; Bronchodilators; Inhalation therapy; Mechanical ventilation; Prostacyclin; Surfactant

Indexed keywords

ACETYLCYSTEINE; AMINOGLYCOSIDE; AMPHOTERICIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BECLOMETASONE; BERACTANT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIPALMITOYLPHOSPHATIDYLCHOLINE; DORNASE ALFA; FENOTEROL; ILOPROST; IPRATROPIUM BROMIDE; LEVALBUTEROL; LUCINACTANT; LUSUPULTIDE; MUCOLYTIC AGENT; ORCIPRENALINE; PROSTACYCLIN; PROSTAGLANDIN; PROSTANOID; PROTEIN; RIBAVIRIN; SALBUTAMOL; SALBUTAMOL SULFATE; SILDENAFIL; SURFACTANT; TOBRAMYCIN; UNINDEXED DRUG; UNIPROST;

AEROSOL; AMBULATORY CARE; ARTIFICIAL VENTILATION; ASTHMA; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DEVICE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; HEART ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOKALEMIA; NEBULIZER; RECOMMENDED DRUG DOSE; REVIEW;

ADRENAL CORTEX HORMONES; AEROSOLS; ANTI-BACTERIAL AGENTS; BRONCHODILATOR AGENTS; CONTINUOUS POSITIVE AIRWAY PRESSURE; CRITICAL CARE; HUMANS; METERED DOSE INHALERS; PROSTAGLANDINS I; RESPIRATION, ARTIFICIAL; SURFACE-ACTIVE AGENTS;

EID: 33846038094     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e328012e022     Document Type: Review

References (99)

1. Dhand R. Inhalation therapy with metered-dose inhalers and dry powder inhalers in mechanically ventilated patients. Respir Care 2005; 50:1331-1334; discussion 1344-1335.
2. Dhand R. Basic techniques for aerosol delivery during mechanical ventilation. Respir Care 2004; 49:611-622.
3. Vecellio L, Guerin C, Grimbert D, et al. In vitro study and semiempirical model for aerosol delivery control during mechanical ventilation. Intensive Care Med 2005; 31:871-876. These investigators determined the factors influencing drug delivery from a nebulizer in a bench model of mechanical ventilation. Once the drug output/minute was known, the time required to deliver a predetermined quantity of drug under the specified ventilatory conditions could be estimated.
4. Labiris NR, Dolovich MB. Pulmonary drug delivery Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003; 56:600-612.
5. Dhand R. Tobin M, editor. Bronchodilator therapy. 2nd ed. New York: McGraw Hill; 2006. This provides a comprehensive review of all aspects of inhaled bronchodilator therapy in mechanically ventilated patients.
6. Dhand R, Tobin MJ. Inhaled bronchodilator therapy in mechanically ventilated patients. Am J Respir Crit Care Med 1997; 156:3-10.
7. Rau J, Dunlevy C, Hill P. A comparison of inline MDI actuators for delivery of a beta agonist and a corticosteroid with a mechanically-ventilated lung model. Respiratory Care 1998; 43:705-712.
8. Fink JB, Dhand R, Grychowski J, et al. Reconciling in vitro and in vivo measurements of aerosol delivery from a metered-dose inhaler during mechanical ventilation and defining efficiency-enhancing factors. Am J Respir Crit Care Med 1999; 159:63-68.
9. Newman SP, Pavia D, Moren F, et al. Deposition of pressurised aerosols in the human respiratory tract. Thorax 1981; 36:52-55.
10. Dolovich M, Ruffin RE, Roberts R, Newhouse MT. Optimal delivery of aerosols from metered dose inhalers. Chest 1981; 80:911-915.
11. Miller DD, Amin MM, Palmer LB, et al. Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation. Am J Respir Crit Care Med 2003; 168:1205-1209.
12. Dhand R, Duarte AG, Jubran A, et al. Dose-response to bronchodilator delivered by metered-dose inhaler in ventilator-supported patients. Am J Respir Crit Care Med 1996; 154:388-393.
13. Duarte AG, Momii K, Bidani A. Bronchodilator therapy with metered-dose inhaler and spacer versus nebulizer in mechanically ventilated patients: comparison of magnitude and duration of response. Respir Care 2000; 45:817-823.
14. Yang SC, Yang SP, Lee TS. Nebulized ipratropium bromide in ventilator-assisted patients with chronic bronchitis. Chest 1994; 105:1511-1515.
15. Fernandez A, Munoz J, de la Calle B, et al. Comparison of one versus two bronchodilators in ventilated COPD patients. Intensive Care Med 1994; 20:199-202.
16. Tzoufi M, Mentzelopoulos SD, Roussos C, Armaganidis A. The effects of nebulized salbutamol, external positive end-expiratory pressure, and their combination on respiratory mechanics, hemodynamics, and gas exchange in mechanically ventilated chronic obstructive pulmonary disease patients. Anesth Analg 2005; 101:843-850. These investigators determined the effect of adding external positive end-expiratory pressure to inhaled albuterol on respiratory mechanics in stable mechanically-ventilated patients with COPD. Application of external PEEP, to counterbalance the effects of intrinsic PEEP, had additive effects to those observed after administration of albuterol.
17. Manthous CA, Hall JB, Schmidt GA, Wood LD. Metered-dose inhaler versus nebulized albuterol in mechanically ventilated patients. Am Rev Respir Dis 1993; 148:1567-1570.
18. Mouloudi E, Maliotakis C, Kondili E, et al. Duration of salbutamol-induced bronchodilation delivered by metered-dose inhaler in mechanically ventilated COPD patients. Monaldi Arch Chest Dis 2001; 56:189-194.
19. Spahr-Schopfer IA, Lerman J, Cutz E, et al. Proximate delivery of a large experimental dose from salbutamol MDI induces epithelial airway lesions in intubated rabbits. Am J Respir Crit Care Med 1994; 150:790-794.
20. Silverglade A. Cardiac toxicity of aerosol propellants. Jama 1972; 222:827-828.
21. Gluck EH, Onorato DJ, Castriotta R. Helium-oxygen mixtures in intubated patients with status asthmaticus and respiratory acidosis. Chest 1990; 98:693-698.
22. Gerbeaux P, Gainnier M, Boussuges A, et al. Use of heliox in patients with severe exacerbation of chronic obstructive pulmonary disease. Crit Care Med 2001; 29:2322-2324.
23. Tassaux D, Jolliet P, Roeseler J, Chevrolet JC. Effects of helium-oxygen on intrinsic positive end-expiratory pressure in intubated and mechanically ventilated patients with severe chronic obstructive pulmonary disease. Crit Care Med 2000; 28:2721-2728.
24. Lee DL, Lee H, Chang HW, et al. Heliox improves hemodynamics in mechanically ventilated patients with chronic obstructive pulmonary disease with systolic pressure variations. Crit Care Med 2005; 33:968-973.
25. Jolliet P, Tassaux D, Thouret JM, Chevrolet JC. Beneficial effects of helium: oxygen versus air:oxygen noninvasive pressure support in patients with decompensated chronic obstructive pulmonary disease. Crit Care Med 1999; 27:2422-2429.
26. Tassaux D, Jolliet P, Thouret JM, et al. Calibration of seven ICU ventilators for mechanical ventilation with helium-oxygen mixtures. Am J Respir Crit Care Med 1999; 160:22-32.
27. Habib DM, Garner SS, Brandeburg S. Effect of helium-oxygen on delivery of albuterol in a pediatric, volume-cycled, ventilated lung model. Pharmacotherapy 1999; 19:143-149.
28. Goode ML, Fink JB, Dhand R, Tobin MJ. Improvement in aerosol delivery with helium-oxygen mixtures during mechanical ventilation. Am J Respir Crit Care Med 2001; 163:109-114.
29. Hess DR, Acosta FL, Ritz RH, et al. The effect of heliox on nebulizer function using a beta-agonist bronchodilator. Chest 1999; 115:184-189.
30. Bihari D, Smithies M, Gimson A, Tinker J. The effects of vasodilation with prostacyclin on oxygen delivery and uptake in critically ill patients. N Engl J Med 1987; 317:397-403.
31. Radermacher P, Santak B, Wust HJ, et al. Prostacyclin for the treatment of pulmonary hypertension in the adult respiratory distress syndrome: effects on pulmonary capillary pressure and ventilation-perfusion distributions. Anesthesiology 1990; 72:238-244.
32. Meyer J, Theilmeier G, Van Aken H, et al. Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure. Anesth Analg 1998; 86:753-758.
33. Putensen C, Hormann C, Kleinsasser A, Putensen-Himmer G. Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 157:1743-1747.
34. Walmrath D, Schneider T, Schermuly R, et al. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153:991-996.
35. Zwissler B, Kemming G, Habler O, et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med 1996; 154:1671-1677.
36. Walmrath D, Schneider T, Pilch J, et al. Effects of aerosolized prostacyclin in severe pneumonia. Impact of fibrosis. Am J Respir Crit Care Med 1995; 151:724-730.
37. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342:1866-1870.
38. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322-329.
39. Leuchte HH, Schwaiblmair M, Baumgartner RA, et al. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest 2004; 125:580-586.
40. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136:515-522.
41. Voswinckel R, Ghofrani HA, Grimminger F, et al. Inhaled treprostinil for treatment of chronic pulmonary arterial hypertension. Ann Intern Med 2006; 144:149-150. Administration of inhaled treprostinil (15mm) to three patients with severe pulmonary hypertension led to a significant reduction in pulmonary vascular resistance that was sustained for >180 min. In two patients inhlaed treprostinil (four doses of 15 μg each) were continued long-term with dramatic improvements in functional capacity.
42. Villar J, Blazquez MA, Lubillo S, et al. Pulmonary hypertension in acute respiratory failure. Crit Care Med 1989; 17:523-526.
43. Lewis JF, Jobe AH. Surfactant and the adult respiratory distress syndrome. Am Rev Respir Dis 1993; 147:218-233.
44. Davidson WJ, Dorscheid D, Spragg R, et al. Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-analysis. Crit Care 2006; 10:R41.
45. Spragg RG, Gilliard N, Richman P, et al. Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome. Chest 1994; 105:195-202.
46. Walmrath D, Gunther A, Ghofrani HA, et al. Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. Am J Respir Crit Care Med 1996; 154:57-62.
47. Wiswell TE, Smith RM, Katz LB, et al. Bronchopulmonary segmental lavage with Surfaxin (KL(4)-surfactant) for acute respiratory distress syndrome. Am J Respir Crit Care Med 1999; 160:1188-1195.
48. Spragg RG, Lewis JF, Wurst W, et al. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med 2003; 167:1562-1566.
49. Anzueto A, Baughman RP, Guntupalli KK, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. N Engl J Med 1996; 334:1417-1421.
50. Weg JG, Balk RA, Tharratt RS, et al. Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. JAMA 1994; 272:1433-1438.
51. Lewis JF, Ikegami M, Jobe AH, Absolom D. Physiologic responses and distribution of aerosolized surfactant (Survanta) in a nonuniform pattern of lung injury. Am Rev Respir Dis 1993; 147:1364-1370.
52. Spragg RG, Lewis JF, Walmrath HD, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med 2004; 351:884-892.
53. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165:867-903.
54. Campbell III PW, Saiman L. Use of aerosolized antibiotics in patients with cystic fibrosis. Chest 1999; 116:775-788.
55. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340:23-30.
56. Feeley TW, Du Moulin GC, Hedley-Whyte J, et al. Aerosol polymyxin and pneumonia in seriously ill patients. N Engl J Med 1975; 293:471-475.
57. Palmer LB, Smaldone GC, Simon SR, et al. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit Care Med 1998; 26:31-39.
58. Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000; 162:328-330.
59. Michalopoulos A, Kasiakou SK, Mastora Z, et al. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005; 9:R53-R59.
60. Adair CG, Gorman SP, Byers LM, et al. Eradication of endotracheal tube biofilm by nebulised gentamicin. Intensive Care Med 2002; 28:426-431.
61. Adair CG, Gorman SP, Feron BM, et al. Implications of endotracheal tube biofilm for ventilator-associated pneumonia. Intensive Care Med 1999; 25:1072-1076.
62. Smith DW, Frankel LR, Mathers LH, et al. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 1991; 325:24-29.
63. Zandstra DF, Stoutenbeek CP, Miranda DR. Effect of mucolytic and bronchodilator aerosol therapy on airway resistance in mechanically ventilated patients. Intensive Care Med 1985; 11:316-318.
64. Fernandez R, Sole J, Blanch L, Artigas A. The effect of short-term instillation of a mucolytic agent (mesna) on airway resistance in mechanically ventilated patients. Chest 1995; 107:1101-1106.
65. Merkus PJ, de Hoog M, van Gent R, de Jongste JC. DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis. Eur Respir J 2001; 18:734-737.
66. Merz U, Kusenbach G, Hausler M, et al. Inhaled budesonide in ventilator-dependent preterm infants: a randomized, double-blind pilot study. Biol Neonate 1999; 75:46-53.
67. Cole CH, Colton T, Shah BL, et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med 1999; 340:1005-1010.
68. O'Riordan TG, Palmer LB, Smaldone GC. Aerosol deposition in mechanically ventilated patients. Optimizing nebulizer delivery. Am J Respir Crit Care Med 1994; 149:214-219.
69. Diot P, Morra L, Smaldone GC. Albuterol delivery in a model of mechanical ventilation: Comparison of metered-dose inhaler and nebulizer efficiency. Am J Respir Crit Care Med 1995; 152:1391-1394.
70. Gay PC, Patel HG, Nelson SB, et al. Metered dose inhalers for bronchodilator delivery in intubated, mechanically ventilated patients. Chest 1991; 99:66-71.
71. Guerin C, Chevre A, Dessirier P, et al. Inhaled fenoterol-ipratropium bromide in mechanically ventilated patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159:1036-1042.
72. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005; 127:335-371. Pertinent randomized controlled trials related to use of pMDIs, with or without spacer/holding chamber, versus dry powder inhalers versus nebulizers as delivery systems for β-agonists, anticholinergics, and corticosteroids in several commonly encountered clinical settings and patient populations were analyzed. Each of the delivery devices provided similar outcomes in patients using the correct technique of inhalation.
73. Alvine GF, Rodgers P, Fitzsimmons KM, Ahrens RC. Disposable jet nebulizers. How reliable are they? Chest 1992; 101:316-319.
74. Loffert DT, Ikle D, Nelson HS. A comparison of commercial jet nebulizers. Chest 1994; 106:1788-1792.
75. Hess D, Fisher D, Williams P, et al. Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand. Chest 1996; 110:498-505.
76. Sterk PJ, Plomp A, van de Vate JF, Quanjer PH. Physical properties of aerosols produced by several jet- and ultrasonic nebulizers. Bull Eur Physiopathol Respir 1984; 20:65-72.
77. Hess DR, Dillman C, Kacmarek RM. In vitro evaluation of aerosol bronchodilator delivery during mechanical ventilation: pressure-control vs volume control ventilation. Intensive Care Med 2003; 29:1145-1150.
78. Craven DE, Lichtenberg DA, Goularte TA, et al. Contaminated medication nebulizers in mechanical ventilator circuits. Source of bacterial aerosols. Am J Med 1984; 77:834-838.
79. Hamill RJ, Houston ED, Georghiou PR, et al. An outbreak of Burkholderia (formerly Pseudomonas) cepacia respiratory tract colonization and infection associated with nebulized albuterol therapy. Ann Intern Med 1995; 122:762-766.
80. Beaty CD, Ritz RH, Benson MS. Continuous in-line nebulizers complicate pressure support ventilation. Chest 1989; 96:1360-1363.
81. Summer W, Elston R, Tharpe L, et al. Aerosol bronchodilator delivery methods. Relative impact on pulmonary function and cost of respiratory care. Arch Intern Med 1989; 149:618-623.
82. Bowton DL, Goldsmith WM, Haponik EF. Substitution of metered-dose inhalers for hand-held nebulizers. Success and cost savings in a large, acute-care hospital. Chest 1992; 101:305-308.
83. Ely EW, Baker AM, Evans GW, Haponik EF. The distribution of costs of care in mechanically ventilated patients with chronic obstructive pulmonary disease. Crit Care Med 2000; 28:408-413.
84. Ballard J, Lugo RA, Salyer JW. A survey of albuterol administration practices in intubated patients in the neonatal intensive care unit. Respir Care 2002; 47:31-38.
85. Mehta S, Hill NS. Noninvasive ventilation. Am J Respir Crit Care Med 2001; 163:540-577.
86. Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995; 333:817-822.
87. Bott J, Carroll MP, Conway JH, et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet 1993; 341:1555-1557.
88. Kramer N, Meyer TJ, Meharg J, et al. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 1995; 151:1799-1806.
89. Ram FS, Picot J, Lightowler J, Wedzicha JA. Noninvasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2004; (3):CD004104.
90. Ferrer M, Valencia M, Nicolas JM, et al. Early noninvasive ventilation averts extubation failure in patients at risk: a randomized trial. Am J Respir Crit Care Med 2006; 173:164-170.
91. Shenfield GM, Evans ME, Walker SR, Paterson JW. The fate of nebulized salbutamol (albuterol) administered by intermittent positive pressure respiration to asthmatic patients. Am Rev Respir Dis 1973; 108:501-505.
92. Dolovich MB, Killian D, Wolff RK, et al. Pulmonary aerosol deposition in chronic bronchitis: intermittent positive pressure breathing versus quiet breathing. Am Rev Respir Dis 1977; 115:397-402.
93. Parkes SN, Bersten AD. Aerosol kinetics and bronchodilator efficacy during continuous positive airway pressure delivered by face mask. Thorax 1997; 52:171-175.
94. Chatmongkolchart S, Schettino GP, Dillman C, et al. In vitro evaluation of aerosol bronchodilator delivery during noninvasive positive pressure ventilation: effect of ventilator settings and nebulizer position. Crit Care Med 2002; 30:2515-2519.
95. Fauroux B, Itti E, Pigeot J, et al. Optimization of aerosol deposition by pressure support in children with cystic fibrosis: an experimental and clinical study. Am J Respir Crit Care Med 2000; 162:2265-2271.
96. Branconnier MP, Hess DR. Albuterol delivery during noninvasive ventilation. Respir Care 2005; 50:1649-1653. The effects of the site of the leak port in the circuit on drug delivery were tested in a bench model of non-invasive mechanical ventilation. With a nebulizer, more drug was delivered with the leak port in the circuit than in the mask. The position of the leak port did not influence drug delivery from a pMDI.
97. Nava S, Karakurt S, Rampulla C, et al. Salbutamol delivery during noninvasive mechanical ventilation in patients with chronic obstructive pulmonary disease: a randomized, controlled study. Intensive Care Med 2001; 27:1627-1635.
98. Pollack CV Jr, Fleisch KB, Dowsey K. Treatment of acute bronchospasm with beta-adrenergic agonist aerosols delivered by a nasal bilevel positive airway pressure circuit. Ann Emerg Med 1995; 26:552-557.
99. Jolliet P, Tassaux D, Roeseler J, et al. Helium-oxygen versus air-oxygen noninvasive pressure support in decompensated chronic obstructive disease: a prospective, multicenter study. Crit Care Med 2003; 31:878-884.